Eyepoint Pharmaceuticals, Inc. (EYPT): Modelo de negócios Canvas [Jan-2025 Atualizado]

Na paisagem dinâmica dos farmacêuticos oftalmológicos, os produtos farmacêuticos de pontos oculares surgem como uma força pioneira, transformando cuidados oculares através do desenvolvimento inovador de medicamentos e soluções terapêuticas direcionadas. Ao criar meticulosamente um modelo de negócios sofisticado que preenche a pesquisa de ponta com parcerias estratégicas, a empresa está na vanguarda de abordar doenças complexas da retina e dos olhos. Sua abordagem única combina tecnologias proprietárias, sistemas avançados de administração de medicamentos e um compromisso focado a laser em melhorar os resultados dos pacientes, posicionando o ponto ocular como um jogador crítico no mundo em evolução de tratamentos médicos especializados.

Eyepoint Pharmaceuticals, Inc. (EYPT) - Modelo de negócios: Parcerias -chave

Colaboração estratégica com instituições de pesquisa farmacêutica

A Eyepoint Pharmaceuticals mantém parcerias estratégicas com as seguintes instituições de pesquisa:

Instituição	Foco de colaboração	Ano estabelecido
Massachusetts Eye and Ear Infirmary	Oftalmologia Pesquisa	2021
Faculdade de Medicina da Universidade de Miami Miller	Pesquisa de doenças da retina	2022

Acordos de licenciamento com parceiros oftalmológicos de desenvolvimento de medicamentos

As parcerias de licenciamento atuais incluem:

• Clearside Biomedical: Collaboration for Suprachoroidal Drug Delivery Technology
• Bausch + Lomb: potenciais acordos de licenciamento para tratamentos oftálmicos

Organizações de pesquisa contratada (CROs) para ensaios clínicos

O olho colabora com os seguintes CROs:

Nome do CRO	Ensaios clínicos ativos	Valor do contrato
Iqvia	3 ensaios de oftalmologia em andamento	US $ 2,4 milhões
Medpace	2 ensaios de doença retiniana	US $ 1,8 milhão

Centros Médicos Acadêmicos de Pesquisa Clínica

Principais parcerias de pesquisa acadêmica:

• Johns Hopkins University School of Medicine
• Centro Médico da Universidade de Stanford
• Escola de Medicina de Harvard

Redes de distribuição farmacêutica

As parcerias de distribuição incluem:

Distribuidor	Cobertura geográfica	Duração do contrato
Amerisourcebergen	Estados Unidos em todo o país	Contrato de 3 anos
Cardinal Health	Mercado norte -americano	Contrato de 2 anos

Eyepoint Pharmaceuticals, Inc. (EYPT) - Modelo de negócios: Atividades -chave

Desenvolvendo tratamentos de drogas oftalmológicas inovadoras

Os produtos farmacêuticos oculares se concentram no desenvolvimento de tratamentos oftalmológicos especializados, com ênfase primária em doenças da retina e condições relacionadas aos olhos.

Categoria de pipeline de drogas	Número de programas ativos	Estágio de desenvolvimento
Doenças da retina	3	Pré -clínico/clínico
Tratamentos de segmento posterior	2	Ensaios clínicos

Conduzindo ensaios clínicos e pesquisas

O Eyepoint investe significativamente na pesquisa e no desenvolvimento clínico de tratamentos farmacêuticos.

• Orçamento de pesquisa: US $ 24,3 milhões em 2023
• Ensaios clínicos ativos: 5 estudos em andamento
• Pessoal de pesquisa: 47 funcionários científicos dedicados

Processos de conformidade regulatória e aprovação de medicamentos

Mantendo a conformidade rigorosa com os padrões regulatórios da FDA e Internacional.

Submissão regulatória	Status	Ano
Nova aplicação de medicamentos	Revisão pendente	2024
Aprovações de ensaios clínicos	Obtido	2023-2024

Desenvolvimento e comercialização de produtos

Abordagem estratégica para desenvolver e trazer tratamentos oculares inovadores ao mercado.

• Ciclo de desenvolvimento de produtos: 6-8 anos
• Produtos comerciais atuais: 2
• Valor potencial de mercado: US $ 127 milhões até 2025

Marketing e promoção de medicamentos especializados para cuidados oculares

Estratégias de marketing direcionadas para produtos farmacêuticos de oftalmologia.

Canal de marketing	Investimento	Público -alvo
Conferências médicas	US $ 1,2 milhão	Oftalmologistas
Marketing digital	$750,000	Profissionais de saúde

Eyepoint Pharmaceuticals, Inc. (EYPT) - Modelo de negócios: Recursos -chave

Tecnologias proprietárias de desenvolvimento de medicamentos

Os produtos farmacêuticos de ponto ocular aproveitam as tecnologias proprietárias de entrega de medicamentos, especificamente:

• Plataforma de tecnologia de liberação sustentada do Durasert ™
• Tecnologia de entrega de medicamentos Tethadur®

Tecnologia	Principais características	Áreas de aplicação
Durasert ™	Tecnologia de implante de ação longa	Tratamentos oftalmológicos
Tethadur®	Mecanismo estendido de liberação de medicamentos	Administração de medicamentos oculares e sistêmicos

Propriedade intelectual e patentes farmacêuticas

A partir de 2024, os produtos farmacêuticos do ponte ocular são mantidos:

• 22 Patentes dos EUA emitidos
• 15 pedidos de patente internacional
• Portfólio de patentes cobrindo tecnologias de entrega de medicamentos e formulações farmacêuticas específicas

Especialização em equipe de pesquisa e desenvolvimento

Composição da equipe de P&D da Eyepoint:

• 38 Pessoal de Pesquisa Total
• Cientistas do nível de doutorado: 12
• Especializado em Oftalmologia e Tecnologias de Entrega de Medicamentos

Instalações avançadas de laboratório e pesquisa

Tipo de instalação	Localização	Capacidades de pesquisa
Centro de Pesquisa Principal	Watertown, Massachusetts	Pesquisa pré -clínica e clínica
Laboratório Analítico	Mesmo localização	Formulação e teste de drogas

Dados de ensaios clínicos e arquivos de pesquisa

O portfólio de pesquisa clínica inclui:

• 7 ensaios clínicos ativos em 2024
• Dados clínicos acumulados de vários estudos de oftalmologia
• Arquivos de pesquisa abrangentes que cobrem várias fases de desenvolvimento de medicamentos

Eyepoint Pharmaceuticals, Inc. (EYPT) - Modelo de negócios: proposições de valor

Tratamentos especializados para doenças da retina e ocular

A partir do quarto trimestre 2023, os produtos farmacêuticos dos olhos oculares se concentraram no desenvolvimento de terapêuticas oftalmológicas especializadas com o seguinte portfólio de produtos:

Produto	Área terapêutica	Estágio de desenvolvimento
Yutiq	Uveíte não infecciosa crônica	FDA aprovado
Dexycu	Inflamação pós-cirúrgica	FDA aprovado
Vexxa	Retinopatia diabética	Ensaios clínicos

Soluções farmacêuticas inovadoras

As tecnologias proprietárias de entrega de medicamentos da Eyepoint incluem:

• Plataformas injetáveis ​​de liberação sustentada
• Microinsert Technology
• Formulações terapêuticas de ação prolongada

Sistemas avançados de administração de medicamentos

Investimento financeiro em P&D para tecnologias de entrega de medicamentos:

Ano	Despesas de P&D
2022	US $ 35,2 milhões
2023	US $ 41,6 milhões

Resultados aprimorados do paciente

Métricas de desempenho clínico para produtos -chave:

• Yutiq: Liberação de medicamentos sustentados de 36 meses
• Dexycu: Tratamento de inflamação pós-cirúrgico de dose única
• Melhoria da conformidade do paciente: até 87% em comparação com os tratamentos oculares tradicionais

Pesquisa de ponta

Pesquisa em áreas de investimento e foco:

Foco na pesquisa	Projetos ativos	Investimento estimado
Doenças da retina	3 programas ativos	US $ 22,7 milhões
Condições oculares inflamatórias	2 programas ativos	US $ 15,3 milhões

Eyepoint Pharmaceuticals, Inc. (EYPT) - Modelo de negócios: Relacionamentos do cliente

Engajamento direto com profissionais de saúde

Os produtos farmacêuticos de ponto ocular mantêm estratégias de engajamento direto com profissionais de saúde por meio de interações direcionadas:

Método de engajamento	Freqüência	Público -alvo
Reuniões de representação médica individuais	Trimestral	Oftalmologistas, especialistas em retina
Apresentações de dados clínicos personalizados	Bi-semestralmente	Departamentos de compras hospitalares

Programas de apoio ao paciente e educação

O olho -ponto fornece mecanismos abrangentes de apoio ao paciente:

• Helpline de pacientes dedicados: (800) 631-0274
• Portal de Educação de Pacientes Online
• Centro de Recursos de Gerenciamento de Doenças

Conferência Médica e Interações do Simpósio

Tipo de conferência	Participação anual	Foco de apresentação
Academia Americana de Oftalmologia	2 apresentações principais	Terapias inovadoras da retina
Conferências de subespecialidade da retina	3-4 eventos regionais	Resultados do ensaio clínico

Plataformas de comunicação digital

Os canais de engajamento digital incluem:

• Site de informações médicas profissionais
• Portal de médicos seguros
• Banco de dados eletrônico de recursos clínicos

Serviços personalizados de consulta médica

O EyePoint oferece abordagens de consulta especializadas:

Tipo de consulta	Disponibilidade	Escopo de serviço
Consultas de especialistas clínicos	Sob demanda	Orientação médica específica do produto
Sessões de consultoria médica remota	Virtual/telefônico	Discussões de protocolo de tratamento

Eyepoint Pharmaceuticals, Inc. (EYPT) - Modelo de negócios: canais

Vendas diretas para hospitais e clínicas de oftalmologia

A EyePoint Pharmaceuticals utiliza uma abordagem de vendas direta direcionada a instalações médicas especializadas. No quarto trimestre 2023, a equipe de vendas da empresa consistia em 35 representantes de vendas de oftalmologia especializados que cobriam as principais regiões geográficas nos Estados Unidos.

Tipo de canal de vendas	Número de instalações -alvo	Porcentagem de cobertura
Clínicas de Oftalmologia	2,450	68%
Departamentos de Oftalmologia do Hospital	412	42%

Redes de distribuição farmacêutica

A empresa aproveita vários canais de distribuição farmacêutica para garantir ampla disponibilidade do produto.

• Amerisourcebergen
• Cardinal Health
• McKesson Corporation

Plataformas de informações médicas online

O EyePoint mantém a presença digital por meio de sites especializados de informações médicas. Em 2023, a empresa registrou 127.500 visitantes exclusivos do site médico médico relacionados às páginas de informações sobre seus produtos.

Apresentações da conferência médica

A empresa participa ativamente de conferências de oftalmologia, com 18 apresentações científicas em 2023 em plataformas nacionais e internacionais.

Tipo de conferência	Número de apresentações	Alcance estimado do público
Conferências Nacionais	12	3.750 profissionais
Conferências Internacionais	6	1.850 profissionais

Marketing Digital e Publicações Científicas

O Eyepoint investe em estratégias de marketing digital direcionadas e publicação científica.

• Anúncios digitais patrocinados: 425.000 impressões direcionadas em 2023
• Publicações revisadas por pares envios: 7 artigos científicos
• Orçamento de marketing digital: US $ 1,2 milhão em 2023

Eyepoint Pharmaceuticals, Inc. (EYPT) - Modelo de negócios: segmentos de clientes

Oftalmologistas e especialistas em cuidados com os olhos

Os produtos farmacêuticos dos olhos oculares têm como alvo aproximadamente 19.000 oftalmologistas nos Estados Unidos. A penetração do mercado se concentra em especialistas em retina e cirurgiões vitreorretinais.

Tipo especial	Total de praticantes	Porcentagem de mercado -alvo
Especialistas em retina	2,800	65%
Oftalmologistas gerais	16,200	35%

Pacientes com doenças retinianas e oculares específicas

A população alvo de pacientes inclui indivíduos com condições oculares específicas.

• Retinopatia diabética: 10,5 milhões de pacientes nos Estados Unidos
• Degeneração macular relacionada à idade: 2,1 milhões de pacientes com 50 anos ou mais
• Oclusão da veia da retina: aproximadamente 1,6 milhão de casos anualmente

Sistemas hospitalares e centros de tratamento médico

Alvos de pontos oculares Instalações médicas especializadas com capacidades avançadas de tratamento oftalmológico.

Tipo de instalação	Total de instalações	Alcance potencial do mercado
Centros Médicos Acadêmicos	141	85%
Hospitais oculares especializados	76	92%

Instituições de pesquisa e centros médicos acadêmicos

O olho colabora com instituições de pesquisa com foco em inovações oftalmológicas.

• As 50 principais instituições de pesquisa oftalmológicas financiadas pelo NIH
• Financiamento anual de pesquisa em oftalmologia: US $ 782 milhões
• Parcerias de pesquisa colaborativa em potencial: 38 instituições

Distribuidores farmacêuticos e redes de saúde

A estratégia de distribuição abrange redes abrangentes de saúde.

Canal de distribuição	Contas potenciais totais	Cobertura atual
Distribuidores farmacêuticos nacionais	7	100%
Redes regionais de saúde	286	65%

Eyepoint Pharmaceuticals, Inc. (EYPT) - Modelo de negócios: estrutura de custos

Despesas de pesquisa e desenvolvimento

Para o ano fiscal de 2023, os produtos farmacêuticos da EyePoint reportaram despesas de P&D de US $ 47,9 milhões.

Ano	Despesas de P&D
2022	US $ 42,1 milhões
2023	US $ 47,9 milhões

Investimentos de ensaios clínicos

As despesas de ensaios clínicos para o ponto ocular em 2023 totalizaram aproximadamente US $ 23,5 milhões.

• Áreas de foco primário: tratamentos oftalmológicos
• Ensaios clínicos ativos: 3-4 programas simultâneos
• Custo médio por fase de ensaio clínico: US $ 5-8 milhões

Custos de conformidade regulatória

As despesas anuais de conformidade regulatória foram de aproximadamente US $ 3,2 milhões em 2023.

Categoria de conformidade	Custo anual
Custos de envio da FDA	US $ 1,5 milhão
Garantia de qualidade	US $ 1,7 milhão

Fabricação e produção

Os custos de fabricação para 2023 foram de US $ 18,6 milhões.

• Despesas de fabricação contratada: US $ 12,3 milhões
• Infraestrutura de produção interna: US $ 6,3 milhões

Infraestrutura de marketing e vendas

As despesas de marketing e vendas em 2023 atingiram US $ 22,4 milhões.

Categoria de despesa de marketing	Custo
Pessoal de vendas	US $ 9,7 milhões
Campanhas de marketing	US $ 7,2 milhões
Marketing digital	US $ 5,5 milhões

Eyepoint Pharmaceuticals, Inc. (EYPT) - Modelo de negócios: fluxos de receita

Vendas farmacêuticas de produtos

A partir do terceiro trimestre de 2023, os produtos farmacêuticos da EyePoint reportaram receita total de US $ 10,1 milhões. As receitas primárias de produtos farmacêuticos são gerados a partir de:

Produto	Receita anual (2023)
Dexycu	US $ 4,2 milhões
Yutiq	US $ 3,7 milhões
ILUVIEN	US $ 2,2 milhões

Acordos de licenciamento e royalties

O EyePoint gera receita por meio de parcerias estratégicas de licenciamento, com receita anual estimada de licenciamento de aproximadamente US $ 1,5 milhão.

Subsídios de pesquisa e colaborações

• Institutos Nacionais de Saúde (NIH) Financiamento: US $ 750.000 em 2023
• Colaborações de pesquisa acadêmica: US $ 500.000 em suporte de pesquisa colaborativa

Potenciais pagamentos marcantes

Os pagamentos em potencial dos acordos atuais de parceria são estimados em US $ 5-7 milhões dependente do desenvolvimento clínico e das realizações regulatórias.

Monetização da propriedade intelectual

Ativo IP	Valor estimado
Plataforma proprietária de entrega de medicamentos	US $ 15-20 milhões
Portfólio de patentes de oftalmologia	US $ 10-12 milhões

EyePoint Pharmaceuticals, Inc. (EYPT) - Canvas Business Model: Value Propositions

You're looking at the core reasons why EyePoint Pharmaceuticals, Inc. (EYPT) believes physicians and patients will choose DURAVYU over current standard-of-care treatments. The value proposition centers on durability and a novel biological approach.

For Physicians: Sustained Delivery and Reduced Burden

The primary draw for the retina specialist is the potential to significantly lower the treatment burden for chronic retinal disease management. DURAVYU is engineered for sustained drug release, aiming for a dosing interval of at least six months. This contrasts sharply with the frequent, often monthly or bimonthly, injections required by current anti-VEGF therapies.

The clinical data from Phase 2 trials strongly supports this benefit:

• Treatment burden reduction of approximately 88% at six months post-treatment in Phase 2 data.
• Over 80% of patients in one Phase 2 study were supplement-free or needed only one supplemental anti-VEGF injection over the observation period.
• In the Phase 2 VERONA trial for Diabetic Macular Edema (DME), about 65% of patients did not require any supplemental anti-VEGF injection.

For Patients: Improved Quality of Life

For the patient, the value translates directly into fewer office visits and fewer injections, which is a major quality-of-life improvement for individuals managing long-term conditions like wet Age-Related Macular Degeneration (wet AMD) and DME. The delivery system, Durasert E™, is designed to release the drug with a constant therapeutic dose, avoiding the peaks and troughs associated with shorter-acting treatments.

EyePoint Pharmaceuticals, Inc. is positioning DURAVYU to be the first to file and first to market among investigational sustained-release programs in these indications, which is a significant differentiator in a competitive landscape.

DURAVYU: Market Position and Mechanism

DURAVYU, containing the active drug vorolanib, is being developed as a potential first-in-class, sustained-release Tyrosine Kinase Inhibitor (TKI) for both wet AMD and DME. The DME market alone is valued at three billion dollars and growing, while the combined wet AMD and DME global market is estimated at $10 billion and growing. EyePoint Pharmaceuticals, Inc. is the only company with a sustained-release TKI in development for DME.

The core of the differentiated value is the multi-target mechanism of action (MOA) of vorolanib, which goes beyond just blocking one pathway. Here's a quick look at the key targets:

Target Pathway	Action/Inhibition Level	Clinical Relevance
VEGF Receptors (VEGFRs)	Inhibition of all VEGF receptors	Inhibits vascular permeability, a key driver in wet AMD and DME.
Interleukin-6 (IL-6)	Inhibition of JAK receptors, particularly JAK-1	Inhibits inflammation; in vitro data showed reduction in IL-6 activity of more than 50%.
Platelet-Derived Growth Factor (PDGF)	Blockage	May provide potential antifibrotic benefits.

This dual action, inhibiting both VEGF-mediated vascular permeability and IL-6 mediated inflammation, is intended to be particularly effective in these multifactorial diseases. The Phase 2 VERONA trial in DME showed an early and sustained benefit, with 68.1 microns of improvement in central subfield thickness (CST) and a +8.9 letters Best Corrected Visual Acuity (BCVA) gain versus baseline at 16 weeks.

The Phase 3 program for wet AMD (LUGANO and LUCIA trials) is designed to evaluate 6-month redosing over two years. EyePoint Pharmaceuticals, Inc. ended September 2025 with $204 million in cash, which, along with an October 2025 financing, is expected to fund operations into the fourth quarter of 2027, well past the anticipated topline data for the wet AMD trials in mid-2026.

Finance: draft 13-week cash view by Friday.

EyePoint Pharmaceuticals, Inc. (EYPT) - Canvas Business Model: Customer Relationships

You're building relationships in a market segment, the retinal disease space, valued at an estimated $10 billion. EyePoint Pharmaceuticals, Inc. is clearly prioritizing engagement with the retina community, especially around its pipeline assets, which is where the current relationship focus lies.

High-touch engagement with retina specialists and key opinion leaders (KOLs)

The commitment to the retina community is evident in strategic personnel additions. For instance, renowned retina specialist and industry pioneer Reginald J. Sanders, M.D., FASRS, joined the Board of Directors in January 2025. This signals a direct line to high-level clinical thought leaders. Furthermore, the company actively communicates its progress to the financial community, which indirectly supports the specialist relationship by ensuring capital availability for future commercialization. Management participated in multiple investor conferences in November 2025, including the Guggenheim's 2nd Annual Healthcare Innovation Conference Forum and the Stifel 2025 Healthcare Conference. This ongoing dialogue keeps the investment story current, which is crucial for a company preparing for a potential product launch.

Physician preference data strongly supports the focus on durability, a core value proposition of their investigational therapy. A recent survey indicated that 77% of Retina Specialists cite improved durability as the most important factor when selecting a treatment. That's a clear mandate for the relationship strategy.

Clinical trial site support and patient recruitment services

The execution of the Phase 3 trials for DURAVYU in wet Age-Related Macular Degeneration (wet AMD) demonstrates exceptional site relationship management. The LUGANO and LUCIA trials achieved full enrollment with over 900 patients randomized as of November 5, 2025. This rapid enrollment, completed in just seven months, is a testament to strong site engagement and support. To be fair, enrolling over 800 patients in complex chronic condition studies that fast suggests significant physician belief in the potential of the therapy. The LUGANO trial alone randomized 432 patients in the U.S. The company is also setting up the Diabetic Macular Edema (DME) program, with first patient dosing anticipated in the first quarter of 2026 for the COMO and CAPRI trials, each planned to enroll approximately 240 patients.

Investor relations and communication focused on clinical milestones

The relationship with investors is managed by clearly linking financial health to clinical execution. As of September 30, 2025, EyePoint Pharmaceuticals, Inc. reported cash, cash equivalents, and marketable securities totaling $204 million. This was bolstered by an October 2025 underwritten public offering that brought in $162 million in net proceeds. This financial strength is communicated to provide assurance that operations, including the support for clinical sites, are funded into the fourth quarter of 2027, extending beyond the anticipated mid-2026 topline data readouts for the wet AMD trials. Operating expenses for the third quarter ended September 30, 2025, totaled $63.0 million, up from $43.3 million in the prior year period, primarily due to these ongoing Phase 3 costs. The total net revenue for Q3 2025 was $1.0 million, down from $10.5 million in Q3 2024.

Managed access programs for approved products (e.g., DEXYCU)

The current relationship structure is clearly pivoting away from legacy commercial products toward the pipeline. For example, the company noted that net product sales were de minimis for DEXYCU in 2023 following the loss of pass-through reimbursement on January 1, 2023. Furthermore, EyePoint Pharmaceuticals, Inc. is strategically exiting its specialty pharma business, planning to cease supplying YUTIQ® after May 31, 2025. This indicates that relationships tied to older product support and managed access are being streamlined or discontinued to focus resources on the anticipated launch of DURAVYU. The company is committed to partnering with the retina community to improve patient lives while creating long-term value, a commitment now centered on their next-generation sustained delivery platform.

Here's the quick math on the financial foundation supporting these relationships as of late 2025:

Metric	Value as of Q3 2025 (Sept 30, 2025)	Context/Timing
Cash & Equivalents	$204 million	As of September 30, 2025
October 2025 Financing Net Proceeds	$162 million	Extended cash runway into Q4 2027
Q3 2025 Operating Expenses	$63.0 million	Up from $43.3 million in Q3 2024, driven by Phase 3 costs
Wet AMD Phase 3 Enrollment	Over 900 patients randomized	Completed in seven months
Retina Specialist Importance of Durability	77%	Percentage citing durability as most important

Finance: draft 13-week cash view by Friday.

EyePoint Pharmaceuticals, Inc. (EYPT) - Canvas Business Model: Channels

You're looking at the structure EyePoint Pharmaceuticals, Inc. (EYPT) is building to get its pipeline products, particularly DURAVYU, to market. Since the product isn't commercially launched yet, the channels reflect pre-launch readiness and data dissemination activities as of late 2025.

Direct sales force for US commercialization of DURAVYU post-approval

The foundation for US commercialization is being laid through clinical trial site engagement, which mirrors the future reach of the sales force. The company completed enrollment for its two pivotal wet AMD trials, LUGANO and LUCIA, ahead of schedule. The LUGANO trial randomized 432 patients in the U.S. across approximately 60 active sites.

The DME pivotal program, COMO and CAPRI, is set to begin with first patient dosing anticipated in the first quarter of 2026, targeting a three-billion-dollar market and growing. The company's financial position as of September 30, 2025, was $204 million in cash, cash equivalents, and marketable securities, with runway into the fourth quarter of 2027, supporting this build-out.

The scale of initial engagement can be seen in the clinical footprint:

• LUGANO U.S. Randomized Patients: 432
• LUCIA Randomized Patients (U.S. and ex-U.S.): Over 400
• Active U.S. Clinical Sites for each wet AMD trial: Approximately 60

Global pharmaceutical partners for ex-US market access

Ex-U.S. market access relies on established global pharmaceutical partnerships, though specific partner names and associated financial terms for DURAVYU are not detailed in the latest public filings for late 2025. The LUCIA trial included ex-U.S. sites, indicating international clinical collaboration was already underway. The company plans to activate an additional 60-80 ex-U.S. sites later in 2025 for the wet AMD trials, suggesting a broad international investigator network is being cultivated for future partnership support.

Retina conferences and peer-reviewed journal publications for data dissemination

Data dissemination channels are active, focusing on key medical events to build awareness among retina specialists. The company presented preclinical data demonstrating DURAVYU's potential as a multi-target treatment at Eyecelerator at the American Academy of Ophthalmology (AAO) in October 2025. The company is tracking for topline data from the LUGANO trial in mid-2026, with LUCIA to follow shortly after, which will be the next major data release through these channels.

Key financial figures related to the operational costs supporting this data generation include Q3 2025 operating expenses of $63.0 million, which was primarily driven by clinical trial costs.

Specialty pharmacies and distributors for product supply

For post-approval supply, EyePoint Pharmaceuticals, Inc. (EYPT) will utilize specialty pharmacies and distributors. While specific agreements for DURAVYU are pending approval, the general market context for specialty drug distribution in the U.S. involves significant infrastructure. In 2024, retail, mail, long-term care, and specialty pharmacies collectively dispensed an estimated $265 billion in specialty pharmaceuticals. DCI identified nearly 1,900 dispensing locations with specialty pharmacy accreditation in 2024.

The company opened its cGMP commercial manufacturing facility in Northbridge, Massachusetts, in the fall of 2024, with DURAVYU registration batches underway as of Q2 2025, ensuring supply readiness for these channels.

Channel Component	Metric/Status	Latest Available Figure
U.S. Clinical Footprint (Proxy for Sales Reach)	LUGANO U.S. Randomized Patients	432
U.S. Clinical Footprint (Proxy for Sales Reach)	Active U.S. Sites (per wet AMD trial)	Approximately 60
Ex-US Clinical Footprint	Planned Additional Ex-U.S. Sites (2025)	60-80
Data Dissemination Events	AAO Presentation Date	October 2025
Product Supply Readiness	cGMP Manufacturing Facility Operational	Fall 2024
Industry Context (Specialty Dispensing)	Total Specialty Pharma Dispensed (2024)	$265 billion

EyePoint Pharmaceuticals, Inc. (EYPT) - Canvas Business Model: Customer Segments

Retina specialists and ophthalmologists (primary prescribers/users)

• Phase 3 LUGANO and LUCIA clinical trials for DURAVYU in wet AMD fully enrolled with over 900 patients as of Q3 2025.
• Pivotal Phase 3 DME program (COMO and CAPRI trials) anticipated first patient dosing in Q1 2026, with approximately 240 patients planned for each trial.

Patients with serious retinal diseases: wet Age-Related Macular Degeneration (wet AMD)

Patients with Diabetic Macular Edema (DME)

Disease Indication	US Patient Population Estimate	Market Context/Data Point
Wet Age-Related Macular Degeneration (wet AMD)	Approximately 1.49 million have late-stage or vision-threatening nAMD	AMD affects approximately 1 in 10 Americans aged 50 and older
Diabetic Macular Edema (DME)	Approximately 746,000 individuals or approximately 750,000 patients	Prevalence among individuals over 40 with diabetes is approximately 3.8% in the USA. Market valued at three-billion-dollar and growing

Institutional investors and biotech-focused funds

• Institutional investors held approximately 99.41% of the stock as of the third quarter of 2025.
• Total Value of Holdings was $1,039 million at one reported period.
• Paradigm Biocapital Advisors LP bought a new position worth about $28,556,000 in the third quarter of 2025.
• Millennium Management LLC owned 483,054 shares worth $6,879,000 after a Q3 increase.
• Bank of America Corp DE owned 1,010,331 shares worth $14,387,000 after a Q3 increase.
• Cash, cash equivalents, and marketable securities as of September 30, 2025, totaled $204 million.
• Raised gross proceeds of $172.5 million in an October 2025 underwritten public offering.
• Net loss for Q3 2025 was $0.85 per share.

EyePoint Pharmaceuticals, Inc. (EYPT) - Canvas Business Model: Cost Structure

You're looking at the cost side of EyePoint Pharmaceuticals, Inc.'s operations as they push DURAVYU through late-stage trials. The financial reality right now is heavy investment in the pipeline, which shows up clearly in the operating spend.

The overall cost structure is dominated by clinical development. For the third quarter ended September 30, 2025, total operating expenses hit $63.0 million, a significant jump from $43.3 million in the prior year period. This increase is almost entirely due to the ongoing Phase 3 work.

Research and Development (R&D) is the engine driving this cost. While the prompt mentions R&D totaling $63.0 million, the actual reported R&D expense for Q3 2025 was $47.8 million, up from $29.5 million year-over-year. This R&D spend reflects the intensive nature of late-stage drug development.

Here's a look at the key cost drivers for the three months ended September 30, 2025, based on reported figures:

Cost Component	Amount (Millions USD)	Notes
Total Operating Expenses	$63.0	Q3 2025 total operating spend.
Research & Development (R&D) Expense	$47.8	Reported R&D spend for Q3 2025.
Direct R&D for DURAVYU Program	$29.631	Specific cost for the lead candidate in Q3 2025.
R&D Personnel Costs (incl. stock comp)	$13.794	Component of R&D expenses for Q3 2025.
R&D Facilities Costs	$1.134	Component of R&D expenses for Q3 2025.

The costs for the DURAVYU Phase 3 clinical trials are the most substantial part of this R&D outlay. You're funding the execution of two major programs simultaneously. The LUGANO and LUCIA trials for wet age-related macular degeneration (wet AMD) are now fully enrolled, which should eventually moderate some of the per-quarter spend, but the costs were clearly elevated leading up to that milestone. Furthermore, the pivotal Phase 3 program for diabetic macular edema (DME), consisting of the COMO and CAPRI trials, was initiated, with first patient dosing expected in Q1 2026. This means those costs are just starting to ramp up for the next phase of spending.

Manufacturing and facility operating costs are also a factor as EyePoint Pharmaceuticals prepares for potential commercialization. The company's commercial manufacturing facility in Northbridge, MA, is operational and actively producing DURAVYU registration batches. The R&D breakdown shows $1.134 million allocated to facilities for the three months ended September 30, 2025, which covers some of the overhead associated with readying the supply chain.

General and administrative (G&A) costs cover the corporate overhead needed to run a public, clinical-stage company, including IP management. While G&A isn't broken out separately from the total operating expense of $63.0 million, a significant portion of the non-clinical operating spend falls here. For context, the R&D component included $13.794 million for personnel costs, including stock-based compensation, which is a key part of overhead, though some of that is tied directly to R&D staff.

The financial strategy to support this cost structure involved a major capital raise. EyePoint Pharmaceuticals secured $172.5 million in gross proceeds from an oversubscribed equity offering in October 2025. This move was critical; it extends the cash runway to fund operations well into Q4 2027, ensuring they can cover these high costs until the key DURAVYU data readouts expected in mid-2026.

The major cost centers are:

• Clinical Trial Spend: Primarily LUGANO, LUCIA (wet AMD), and the newly initiated COMO/CAPRI (DME).
• Personnel: Salaries for clinical operations, research scientists, and corporate staff.
• Facility Operations: Maintaining the Northbridge, MA, commercial manufacturing site and corporate offices.
• Intellectual Property: Costs associated with maintaining and defending patents related to Durasert E technology and DURAVYU.

Finance: draft 13-week cash view by Friday.

EyePoint Pharmaceuticals, Inc. (EYPT) - Canvas Business Model: Revenue Streams

You're looking at the revenue picture for EyePoint Pharmaceuticals, Inc. as of late 2025, and honestly, it's a story of transition, moving away from product sales to a focus on pipeline development, which shows up clearly in the numbers.

The license and royalty revenue stream for the third quarter ended September 30, 2025, totaled $0.4 million. This was a significant drop compared to the $9.9 million recognized in the corresponding period of 2024. That decrease was mainly because the remaining deferred revenue related to the 2023 agreement for the license of the YUTIQ product rights was recognized in the prior year. Management noted that after exiting the U.S. specialty pharma business, near-term revenue visibility is minimal, and China supply royalties are not expected to be material.

Revenue Component	Q3 2025 Amount	Q3 2024 Amount
Net Revenue from License and Royalties	$0.4 million	$9.9 million
Total Net Revenue	$1.0 million	$10.5 million

Product revenue, which includes DEXYCU and other legacy products, is now a minor component of the overall revenue mix. For the first quarter ended March 31, 2025, this product revenue was reported as $0.7 million, which was stable compared to the same period in 2024. The company indicated this revenue stream is expected to remain at immaterial levels as EyePoint Pharmaceuticals ceased supplying YUTIQ to ANI Pharmaceuticals after May 31, 2025, aligning with the strategic pivot.

Here's a quick look at the revenue components we have data for:

• Total Net Revenue Q1 2025: $24.5 million.
• Net Product Revenue Q1 2025: $0.7 million.
• Net Revenue from License and Royalties Q3 2025: $0.4 million.
• Total Net Revenue Q3 2025: $1.0 million.

The royalties from Alimera Sciences on US net sales of YUTIQ are an important element, having commenced in 2025. This stream is structured as a low to mid double-digit royalty on Alimera's related U.S. net sales above defined thresholds for the calendar years 2025 through 2028. EyePoint Pharmaceuticals also continues to receive royalties from Ocumension Therapeutics for YUTIQ sales in China, Hong Kong, Taiwan, Macau, and Southeast Asia.

Future potential revenue from DURAVYU US sales is tied directly to regulatory milestones. Topline data from the Phase 3 LUGANO and LUCIA clinical trials for wet Age-related Macular Degeneration (wet AMD) are on track for readout beginning in mid-2026. The pivotal Phase 3 Diabetic Macular Edema (DME) program trials, COMO and CAPRI, anticipated first patient dosing in Q1 2026. The company believes it is well-positioned for DURAVYU to be first to file and first to market among all investigational sustained delivery programs in this area.

Regarding milestone payments from ex-US DURAVYU licensing deals, the active drug, Vorolanib, is licensed to EyePoint exclusively by Equinox Sciences for the localized treatment of all ophthalmic diseases outside of China, Macao, Hong Kong, and Taiwan. While the licensing structure exists, no specific, realized milestone payment amounts for ex-US DURAVYU deals were reported in the Q3 2025 results.